벨로다인 라이더, CES에서 전에 경험하지 못했던 다양한 제품 선보여
 |
Velodyne Lidar Showcases a Wide Array of Never-Before-Seen Products at CES
Velodyne Lidar, Inc. will introduce and demonstrate its breakthrough new lidar sensor technology at CES 2019 in the Las Vegas Convention Center North Hall, booth #9010. Velodyne will present product demonstrations showing how lidar is advancing vehicle autonomy, safety, and advanced driver assistance systems (ADAS). The in-booth press conference will announce exciting collaborations and strategic partnerships, never-before-seen products, and customer achievements on Wednesday, January 9, at 11:0...
벨로다인 라이더, CES에서 전에 경험하지 못했던 다양한 제품 선보여
|
Velodyne Lidar Showcases a Wide Array of Never-Before-Seen Products at CES
Velodyne Lidar, Inc. will introduce and demonstrate its breakthrough new lidar sensor technology at CES 2019 in the Las Vegas Convention Center North Hall, booth #9010. Velodyne will present product demonstrations showing how lidar is advancing vehicle autonomy, safety, and advanced driver assistance systems (ADAS). The in-booth press conference will announce exciting collaborations and strategic partnerships, never-before-seen products, and customer achievements on Wednesday, January 9, at 11:0...
다케다, 새로운 면역-항암제 포트폴리오 개발 위해 세포요법 연구 협업을 다수 추진한다고 발표
다케다제약(Takeda Pharmaceutical Company Limited, 이하 ‘다케다’)(도쿄증권거래소: 4502)이 자사의 핵심 전략 부문인 면역 항암제(I-O) 개발을 위해 새로운 연구 협업을 추진한다고 3일 발표했다. 다케다는 이러한 협업을 통해 난치성 암 환자의 요구를 충족시키는 중요한 기회를 제공할 수 있는 완전히 새로운 세포 요법 접근방식을 포함한 차세대 면역 항암제의 발굴을 촉진하겠다는 방...
Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation cancer immunotherapies, including novel cell therapy approaches that may provide important opportunities for addressing the needs of patients with hard-to-treat cancers.
“We are excited by the recent momentum in oncology R...
다케다, 새로운 면역-항암제 포트폴리오 개발 위해 세포요법 연구 협업을 다수 추진한다고 발표
다케다제약(Takeda Pharmaceutical Company Limited, 이하 ‘다케다’)(도쿄증권거래소: 4502)이 자사의 핵심 전략 부문인 면역 항암제(I-O) 개발을 위해 새로운 연구 협업을 추진한다고 3일 발표했다. 다케다는 이러한 협업을 통해 난치성 암 환자의 요구를 충족시키는 중요한 기회를 제공할 수 있는 완전히 새로운 세포 요법 접근방식을 포함한 차세대 면역 항암제의 발굴을 촉진하겠다는 방...
Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation cancer immunotherapies, including novel cell therapy approaches that may provide important opportunities for addressing the needs of patients with hard-to-treat cancers.
“We are excited by the recent momentum in oncology R...
멀티캠퍼스, ‘OPIc Leader’s Club 16기’ 모집
 |
멀티캠퍼스, ‘OPIc Leader’s Club 16기’ 모집
|